The first MASH drug could open the door for others — including GLP-1s
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive ...
News Medical on MSN37 分钟
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...